Medicare GLP-1 Bridge Coverage Program

Introduction

The Centers for Medicare & Medicaid Services (CMS) plans to expand access to GLP-1 medications for obesity treatment through a temporary initiative called the Medicare GLP-1 Bridge Program. This short-term program will begin on July 1, 2026, and continue through December 31, 2026.

Currently, federal law prevents Medicare from covering medications used solely for weight loss. As a result, many beneficiaries cannot access popular obesity drugs such as Wegovy and Zepbound through standard Medicare benefits. To address this gap, CMS created the Medicare GLP-1 Bridge as a temporary solution before launching a larger demonstration program in 2027.

Understanding the Medicare GLP-1 Bridge Program

The Medicare GLP-1 Bridge program aims to provide temporary coverage for GLP-1 receptor agonists approved for weight reduction. Under this initiative, eligible Medicare beneficiaries can access medications like Wegovy and Zepbound for a $50 copayment per prescription.

However, the program does not function within the traditional Medicare Part D prescription drug benefit. Instead, CMS will manage a centralized processing system for prescriptions and prior authorizations.

How the Program Works

• Beneficiaries must be enrolled in Medicare Part D to participate.
• Physicians will submit prescriptions and authorization requests to a CMS-managed central processor.
• The program will operate independently from the standard Part D benefit.
• Coverage will only apply to GLP-1 medications prescribed specifically for obesity treatment.

Because the program operates outside Part D, certain financial protections normally available to beneficiaries will not apply.

Eligibility Criteria for Beneficiaries

CMS designed the program to target individuals with clinically significant obesity or weight-related health risks.

BMI Requirements

Beneficiaries may qualify if they meet one of the following criteria:

• Body Mass Index (BMI) of 35 or higher, regardless of additional conditions
• BMI of 27 or higher with related clinical risk factors

These criteria align with clinical guidelines commonly used for prescribing GLP-1 medications for obesity management.

Although CMS has not estimated the exact number of participants, previous research suggests that a large population could qualify. According to an analysis by the Kaiser Family Foundation (KFF), nearly 14 million Medicare beneficiaries had a diagnosis of overweight or obesity in 2020.

However, stricter eligibility requirements under the Bridge program will likely reduce the number of qualifying participants.

Potential Benefits for Medicare Patients

The Medicare GLP-1 Bridge could provide meaningful health benefits for many older adults and individuals with disabilities.

Improved Access to Obesity Treatment

GLP-1 medications have gained attention for their ability to support significant weight loss and improve metabolic health. For eligible beneficiaries, the program may:

• Expand access to effective obesity medications
• Reduce barriers to treatment for patients who previously paid out of pocket
• Support better management of weight-related conditions

Growing Demand for GLP-1 Drugs

Demand for GLP-1 therapies continues to increase due to their clinical effectiveness. As obesity rates remain high among older adults, broader medication access could help improve long-term health outcomes.

Limitations and Financial Considerations

Despite its benefits, the program also introduces several challenges.

Copayment Does Not Count Toward Part D Limits

Because the Bridge program operates outside the Part D benefit structure:

• The $50 copayment will not count toward the Part D deductible
• It will not apply toward the $2,100 annual out-of-pocket spending cap

Consequently, beneficiaries who rely on multiple medications may still face significant prescription costs.

Differences for Other GLP-1 Uses

Patients who use GLP-1 medications for type 2 diabetes, sleep apnea, or other approved conditions will continue receiving them through their Part D plans. Those patients must follow their plan’s normal cost-sharing rules, which could exceed the $50 copayment offered through the Bridge program.

Challenges for Low-Income Beneficiaries

Another concern involves individuals who qualify for the Part D Low-Income Subsidy (LIS). These subsidies reduce prescription drug costs under Part D. However, they will not apply to medications dispensed through the Bridge program.

As a result, even the $50 copayment may pose a financial barrier for some low-income beneficiaries.

Transition to the BALANCE Model in 2027

CMS intends for the Bridge program to serve as a temporary step before a larger demonstration initiative called the BALANCE Model, scheduled to launch in 2027.

Voluntary Plan Participation

Unlike the Bridge program, which CMS will mandate temporarily, the BALANCE Model will rely on voluntary participation from Medicare Part D plans.

This transition could create complications for beneficiaries.

For example, patients who receive GLP-1 medications through the Bridge program may need to enroll in a participating Part D plan in order to continue coverage in 2027.

Possible Plan Switching

If their current plan does not participate in the BALANCE model, beneficiaries may need to switch plans during the 2027 Medicare open enrollment period.

Such changes could affect coverage and costs for other medications they take.

Key Takeaways

The Medicare GLP-1 Bridge Program represents an important step toward expanding obesity treatment options for Medicare beneficiaries. It offers temporary access to high-demand GLP-1 medications at a predictable copayment.

However, the program also introduces financial and logistical challenges. The transition to the voluntary BALANCE Model in 2027 may require beneficiaries to adjust their Medicare Part D coverage to maintain access to these medications.